

H⁺ Transporting Two Sector ATPase (F₁F₀ ATP Synthase or ATP Synthase or Mitochondrial ATPase or Bacterial Ca²⁺/Mg²⁺ ATPase or EC 3.6.3.14) - Pipeline Review, H1 2018

<https://marketpublishers.com/r/H2A40C16FD8EN.html>

Date: May 2018

Pages: 44

Price: US\$ 3,500.00 (Single User License)

ID: H2A40C16FD8EN

Abstracts

H⁺ Transporting Two Sector ATPase (F₁F₀ ATP Synthase or ATP Synthase or Mitochondrial ATPase or Bacterial Ca²⁺/Mg²⁺ ATPase or EC 3.6.3.14) - Pipeline Review, H1 2018

SUMMARY

According to the recently published report 'H⁺ Transporting Two Sector ATPase - Pipeline Review, H1 2018'; H⁺ Transporting Two Sector ATPase (F₁F₀ ATP Synthase or ATP Synthase or Mitochondrial ATPase or Bacterial Ca²⁺/Mg²⁺ ATPase or EC 3.6.3.14) pipeline Target constitutes close to 5 molecules. Out of which approximately 3 molecules are developed by companies and remaining by the universities/institutes.

H⁺ Transporting Two Sector ATPase (F₁F₀ ATP Synthase or ATP Synthase or Mitochondrial ATPase or Bacterial Ca²⁺/Mg²⁺ ATPase or EC 3.6.3.14) - ATP synthase (EC 3.6.3.14) is an important enzyme that creates the energy storage molecule adenosine triphosphate (ATP). The majority of cellular energy in the form of adenosine triphosphate (ATP) is synthesized by the ubiquitous F₁F₀ ATP synthase. Power for ATP synthesis derives from an electrochemical proton (or Na⁺) gradient, which drives rotation of membranous F₀ motor components.

The report 'H⁺ Transporting Two Sector ATPase - Pipeline Review, H1 2018' outlays comprehensive information on the H⁺ Transporting Two Sector ATPase (F₁F₀ ATP Synthase or ATP Synthase or Mitochondrial ATPase or Bacterial Ca²⁺/Mg²⁺ ATPase

or EC 3.6.3.14) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.

It also reviews key players involved in H⁺ Transporting Two Sector ATPase (F₁F₀ ATP Synthase or ATP Synthase or Mitochondrial ATPase or Bacterial Ca²⁺/Mg²⁺ ATPase or EC 3.6.3.14) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Phase II and Preclinical stages are 1, 1 and 1 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively. Report covers products from therapy areas Infectious Disease, Gastrointestinal and Immunology which include indications Tuberculosis, Leprosy, Plaque Psoriasis (Psoriasis Vulgaris), Pulmonary Tuberculosis and Ulcerative Colitis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The report provides a snapshot of the global therapeutic landscape for H⁺ Transporting Two Sector ATPase (F₁F₀ ATP Synthase or ATP Synthase or Mitochondrial ATPase or Bacterial Ca²⁺/Mg²⁺ ATPase or EC 3.6.3.14)

The report reviews H⁺ Transporting Two Sector ATPase (F₁F₀ ATP Synthase or ATP Synthase or Mitochondrial ATPase or Bacterial Ca²⁺/Mg²⁺ ATPase or EC 3.6.3.14) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in H⁺ Transporting Two Sector ATPase (F₁F₀ ATP Synthase or ATP Synthase or Mitochondrial ATPase or Bacterial Ca²⁺/Mg²⁺ ATPase or EC 3.6.3.14) targeted therapeutics and enlists all their

major and minor projects

The report assesses H⁺ Transporting Two Sector ATPase (F1F0 ATP Synthase or ATP Synthase or Mitochondrial ATPase or Bacterial Ca²⁺/Mg²⁺ ATPase or EC 3.6.3.14) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to H⁺ Transporting Two Sector ATPase (F1F0 ATP Synthase or ATP Synthase or Mitochondrial ATPase or Bacterial Ca²⁺/Mg²⁺ ATPase or EC 3.6.3.14) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for H⁺ Transporting Two Sector ATPase (F1F0 ATP Synthase or ATP Synthase or Mitochondrial ATPase or Bacterial Ca²⁺/Mg²⁺ ATPase or EC 3.6.3.14)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding H⁺ Transporting Two Sector ATPase (F1F0 ATP Synthase or ATP Synthase or Mitochondrial ATPase or Bacterial Ca²⁺/Mg²⁺ ATPase or EC 3.6.3.14)

development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction

Global Markets Direct Report Coverage

H⁺ Transporting Two Sector ATPase (F₁F₀ ATP Synthase or ATP Synthase or Mitochondrial ATPase or Bacterial Ca²⁺/Mg²⁺ ATPase or EC 3.6.3.14) - Overview

H⁺ Transporting Two Sector ATPase (F₁F₀ ATP Synthase or ATP Synthase or Mitochondrial ATPase or Bacterial Ca²⁺/Mg²⁺ ATPase or EC 3.6.3.14) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

H⁺ Transporting Two Sector ATPase (F₁F₀ ATP Synthase or ATP Synthase or Mitochondrial ATPase or Bacterial Ca²⁺/Mg²⁺ ATPase or EC 3.6.3.14) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

H⁺ Transporting Two Sector ATPase (F₁F₀ ATP Synthase or ATP Synthase or Mitochondrial ATPase or Bacterial Ca²⁺/Mg²⁺ ATPase or EC 3.6.3.14) - Companies Involved in Therapeutics Development

Johnson & Johnson

Lycera Corp

H⁺ Transporting Two Sector ATPase (F₁F₀ ATP Synthase or ATP Synthase or Mitochondrial ATPase or Bacterial Ca²⁺/Mg²⁺ ATPase or EC 3.6.3.14) - Drug Profiles
bedaquiline fumarate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LYC-30937 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit F₀F₁-ATP Synthase for Tuberculosis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit ATP Synthase for Tuberculosis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TMC-207 Back Up - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

H⁺ Transporting Two Sector ATPase (F1F0 ATP Synthase or ATP Synthase or Mitochondrial ATPase or Bacterial Ca²⁺/Mg²⁺ ATPase or EC 3.6.3.14) - Dormant Products

H⁺ Transporting Two Sector ATPase (F1F0 ATP Synthase or ATP Synthase or Mitochondrial ATPase or Bacterial Ca²⁺/Mg²⁺ ATPase or EC 3.6.3.14) - Product Development Milestones

Featured News & Press Releases

Apr 25, 2017: Janssen Files NDA in Japan for Multidrug-Resistant Tuberculosis Drug Bedaquiline Fumarate

Dec 07, 2016: Lycera Announces Initiation of Phase 2 UPRISE Clinical Trial of LYC-30937-EC for Patients with Moderate Psoriasis

Dec 01, 2016: China Food And Drug Administration Approves Sirturo (Bedaquiline) For Patients With Pulmonary Multi-Drug Resistant Tuberculosis (MDR-TB)

Aug 22, 2016: Lycera Announces Initiation of Phase 2 Clinical Trial of LYC-30937-EC in Patients with Ulcerative Colitis

Jun 06, 2016: Speeding up drug discovery to fight tuberculosis

Mar 18, 2016: Lycera Announces Presentation of Positive Preclinical Results for Lead Candidate LYC-30937 at the 11th Congress of the European Crohn's and Colitis Organization (ECCO)

Aug 24, 2015: Janssen's SIRTURO to be commissioned by NHS England for the treatment of multi-drug resistant tuberculosis

Apr 30, 2015: Lycera Initiates Phase 1 Clinical Trial of LYC-30937, a First-In-Class ATPase Modulator for Inflammatory Bowel Disease

Nov 06, 2014: Janssen Collaborates for Continued Evaluation of Multidrug-Resistant Tuberculosis Treatment Regimens with SIRTURO (bedaquiline)

Oct 14, 2014: Bedaquiline Found Effective Against Tuberculosis In Indian Patients: Hinduja Hospital says

Mar 06, 2014: SIRTURO (bedaquiline) Receives Conditional Approval in the European Union for the Treatment of Multi-Drug Resistant Tuberculosis

Dec 20, 2013: SIRTURO Receives Positive Opinion from the Committee for Medicinal Products for Human Use as Part of Combination Therapy to Treat Adults with

Pulmonary Multi-Drug Resistant Tuberculosis

Dec 19, 2013: Pharmstandard announces registration of Sirturo for MDR-TB

Jun 13, 2013: WHO Issues Interim Guidance On Bedaquiline To Treat Multidrug-Resistant Tuberculosis

Dec 31, 2012: FDA Grants Accelerated Approval For Sirturo As Part of Combination Therapy To Treat Adults With Pulmonary Multi-drug Resistant Tuberculosis

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Indication, H1 2018

Number of Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018

Number of Products under Investigation by Universities/Institutes, H1 2018

Products under Investigation by Universities/Institutes, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Pipeline by Johnson & Johnson, H1 2018

Pipeline by Lycera Corp, H1 2018

Dormant Projects, H1 2018

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Top 10 Indications, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

COMPANIES MENTIONED

Johnson & Johnson

Lycera Corp

I would like to order

Product name: H+ Transporting Two Sector ATPase (F1F0 ATP Synthase or ATP Synthase or Mitochondrial ATPase or Bacterial Ca²⁺/Mg²⁺ ATPase or EC 3.6.3.14) - Pipeline Review, H1 2018

Product link: <https://marketpublishers.com/r/H2A40C16FD8EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/H2A40C16FD8EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970